Skip to content
value.today

Mangoceuticals, Inc.

MGRX
$6 Mmarket cap on Oct 20, 2026
#26,613 in the world#4,373 in 🇺🇸 USA
Compare
World rank
#26,613
Revenue
$0 M
For year ending December-2025
Net income
$-21 M
-4487.0% margin
SEC filing
Employees
—

Mangoceuticals, Inc. in brief

Mangoceuticals, Inc. is a listed company, based in Dallas, Texas, USA. Its market value was $6 M on 20 October 2026, which makes it the 26,613th largest listed company in the world and the 4,373rd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $21 M. Its shares trade under the symbol MGRX (Nasdaq).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Mangoceuticals, Inc.

—Material Agreements—Master Services Agreement with Epiq Scripts”, we have entered into an agreement with Epiq Scripts, a related party, 52% owned and controlled by Jacob D. Cohen, our Chairman and Chief Executive Officer, to provide us compounding and other pharmacy services.

Our operations are subject to extensive government regulation, from the entry into agreements with physicians or groups of physicians to provide telehealth services to our potential customers, to the marketing and promotion of our products, the creation of our products, and the sale of our products through licensed pharmacists.

From the company's annual report filed with the US SEC: read the report

Mangoceuticals, Inc. timeline

1 events, 2022
  1. 2022
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.

Events of Mangoceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
20.1×
Price / book
0.4×
Free cash flow yield
-112.5%
Net margin (TTM)
-3554.8%
Operating margin
-3919.6%
Return on equity
-72.5%
Liabilities / assets
5.5%
Revenue growth
-25.8%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2022: revenue —, net income $-2M—FY22Fiscal year ending Dec 2023: revenue $1M, net income $-9M$1MFY23Fiscal year ending Dec 2024: revenue $1M, net income $-9M$1MFY24Fiscal year ending Dec 2025: revenue $0M, net income $-21M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M-25.8%$-18M$-21M-4487.0%
Dec 2024$1M-15.1%$-8M$-9M-1404.8%
Dec 2023$1M—$-9M$-9M-1261.6%
Dec 2022——$-2M$-2M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-6M——$-2.17—
Dec 2024$-5M——$-4.80—
Dec 2023$-7M$0M$-7M$-8.58—
Dec 2022$-1M$0M$-1M$-0.19—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$0M
Net income, trailing 12 months
$-11M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $0M, net income $-2M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-5M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-5M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-8M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-3M$0MDec ’25Three months to Mar 2026: revenue $0M, net income $-3M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-1M$0MJun ’26Three months to Sep 2026: revenue $0M, net income $-4M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M (-12.5% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Mangoceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-18 M
Net income
$-21 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$16 M
Total liabilities
$1 M
Total equity
$15 M

As of December-2025

Top 19 institutional investors in Mangoceuticals, Inc.#

As of Sep 30, 2026
19 institutions held 1.7 M shares (about 7.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 7.4%. Filings read through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 19 largest institutional investors in Mangoceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Geode Capital Management, LLC689,270+533,027 (+341.15%)3.20%$0 MNov 6, 2026
2Jane Street Group, LLC214,629New1.00%$0 MNov 12, 2026
3Citadel Advisors LLC189,004-149,960 (-44.24%)0.88%$0 MNov 16, 2026
4Ikarian Capital, LLC138,1460 (0.00%)0.64%$0 MNov 16, 2026
5Vanguard Capital Management LLC123,0410 (0.00%)0.57%$0 MNov 13, 2026
6Morgan Stanley70,600+69,600 (+6960.00%)0.33%$0 MNov 13, 2026
7Vanguard Fiduciary Trust Co57,1630 (0.00%)0.27%$0 MNov 13, 2026
8Boothbay Fund Management, LLC38,4410 (0.00%)0.18%$0 MNov 16, 2026
9Northern Trust Corp37,5790 (0.00%)0.17%$0 MNov 16, 2026
10Ackerman Capital Advisors, LLC34,5000 (0.00%)0.16%$0 MOct 30, 2026
11StoneX Group Inc.24,099New0.11%$0 MNov 3, 2026
12XTX Topco Ltd22,180-164,076 (-88.09%)0.10%$0 MNov 16, 2026
13ACT Advisors, LLC.12,314-14,549 (-54.16%)0.06%$0 MOct 15, 2026
14Csenge Advisory Group10,0000 (0.00%)0.05%$0 MNov 4, 2026
15Fortitude Family Office, LLC3,074+1,731 (+128.89%)0.01%$0 MOct 14, 2026
16Ameriflex Group, Inc.2,8850 (0.00%)0.01%$0 MNov 16, 2026
17Tower Research Capital LLC (TRC)763-20 (-2.55%)0.00%$0 MNov 16, 2026
18Robinhood Markets, Inc.121—0.00%$0 MNov 18, 2026
19Northwestern Mutual Wealth Management Co100New0.00%$0 MNov 13, 2026

Mutual funds holding Mangoceuticals, Inc.#

5 funds hold shares worth $0 M (about 1.2% of the company). Since their previous reports 1 added shares and 1 sold, selling $0 M net.
Mutual funds holding Mangoceuticals, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC109,105$0 M0.51%<0.01%+37%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.123,041$0 M0.57%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC14,438$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC12,606$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC453$0 M<0.01%<0.01%no changeMay 31, 2026

As of Jun 30, 2026

Insider trading at Mangoceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$21 K
3 sales, 1 insider
Net, 12 months
-$21 K
open market only
Insiders on file
8
since
-$153 K$0Jun 2024: bought $0 (0 trades), sold $40 K (2 trades)Jun 24Nov 2025: bought $0 (0 trades), sold $153 K (1 trades)NovDec 2025: bought $0 (0 trades), sold $21 K (3 trades)Dec
Bought (open market)Sold (open market)Hover a month for the totals
Mangoceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jacob D. CohenChief Executive Officer, Director, 10% ownerGift-2.00 M——0Form 4
filed Jacob D. CohenChief Executive Officer, Director, 10% ownerGift+2.00 M——3.31 MForm 4
filed Alex P. HamiltonDirectorGrant or award+100,000——101,667Form 4
filed Eugene M. JohnstonCFOGrant or award+100,000——220,000Form 4
filed Jacob D. CohenChief Executive Officer, Director, 10% ownerGrant or award+2.00 M——2.00 MForm 4
filed Eugene M. JohnstonCFOSell-3,333$1.170$4 K120,000Form 4
filed Eugene M. JohnstonCFOSell-5,000$1.200$6 K123,333Form 4
filed Eugene M. JohnstonCFOSell-10,000$1.130$11 K128,333Form 4

Markets and events: Mangoceuticals, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
53,343
0.3% of shares · 1 days to cover
Reg SHO threshold list
4 days
in the last 90 days
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-07-31 14:30 UTC, code LUDP, resumed 14:35 UTC
  • 2026-07-31 14:22 UTC, code LUDP, resumed 14:27 UTC
  • 2026-07-31 14:16 UTC, code LUDP, resumed 14:21 UTC
  • 2025-03-25 13:43 UTC, code LUDP, resumed 13:53 UTC
  • 2025-03-25 13:34 UTC, code LUDP, resumed 13:39 UTC

Fails to deliver

  • : 80,014 shares at $0.28
  • : 11,324 shares at $0.45
  • : 23,395 shares at $0.48
  • : 33,439 shares at $0.43
  • : 32,059 shares at $0.44

Mangoceuticals, Inc. scorecard#

Passes 1 of the 10 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 3). Fiscal year 2025; market cap of Oct 20, 2026.

  • Valuation0 of 3
  • Growth0 of 1
  • Profitability0 of 2
  • Financial health1 of 3
  • Shareholder returns0 of 1

Worked out from the statements as filed (sec), the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Mangoceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Mangoceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022
Income statement
Revenue4566167318.9
Cost of revenue54931554.1
Gross profit2503804324.9
General and administrative3,7563,0013,3191,644
Operating expenses18,2838,3529,6501,996
Operating income−18,032−7,972−9,219−1,992
Interest expense and finance costs10414−6.56.5
Other non-operating income (expense)−2,611−7356.5−6.5
Income before tax−20,643−8,707−9,212−1,998
Net income including minority interests−20,643−8,707−9,212—
Minority interests' share of net income−0.5−1.1——
Net income attributable to shareholders−20,643−8,706−9,212−1,998
Earnings per share, basic-2.17-4.80r-8.58r-0.19
Earnings per share, diluted-2.17-4.80r-8.58r-0.19
Shares, weighted average (basic)102.01.1r11
Shares, weighted average (diluted)102.01.1r11
Balance sheet
Cash and cash equivalents1,48659739683r
Inventory——19—
Current assets1,54776835r695
Property, plant and equipment1.82.896117
Right-of-use (leased) assets30859119174
Other intangible assets14,23215,233——
Non-current assets14,54215,295215—
Total assets16,09015,3711,0511,003
Accounts payable41783814134
Current liabilities8911,425211261
Lease liabilities (non-current)——65129
Non-current liabilities——65129
Total liabilities8911,425276389
Retained earnings−40,647−20,004r−11,228−2,016
Shareholders' equity15,20113,946775614
Minority interests−1.5−1.1——
Total equity15,19913,945775614r
Total liabilities and equity16,09015,3711,0511,003
Shares outstanding163.21.4r13
Cash-flow statement
Depreciation and amortization—9.925—
Share-based compensation1,168249624234
Cash from operating activities−5,850−4,864−6,997−1,347
Capital expenditure——−3.5−43
Cash from investing activities—65−3.5−43
Shares issued4,6251,3286,2002,000
Cash from financing activities7,2714,1287,0572,050
Change in cash——56660
Report10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Sep 30, 2026

Events at Mangoceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Acquisition or sale completed 3 · Directors and officers 5 · Material agreement 14 · Agreement ended 4 · New debt 3 · Unregistered share sale 10 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 2

Mangoceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Shareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Shareholder vote8-K
Material agreement8-K
Acquisition or sale completedMaterial agreementUnregistered share sale8-K
Agreement ended8-K
Directors and officersMaterial agreementBylaws or fiscal year changed8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Delisting notice8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Material agreementNew debt8-K
Directors and officersMaterial agreementAgreement endedNew debtUnregistered share sale8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Acquisition or sale completedMaterial agreementAgreement endedUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Bylaws or fiscal year changed8-K
Directors and officers8-K
Unregistered share sale8-K
Material agreementUnregistered share sale8-K
Acquisition or sale completedMaterial agreementAgreement ended8-K
Material agreementNew debtUnregistered share sale8-K

As of Nov 13, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Mangoceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2022$2 MNo. 1Under $2 million19equity, optionsSEC

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Oct 20, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Mangoceuticals, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Mangoceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Mangoceuticals, Inc.? Suggest a correction